[3-Hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate | 157953-13-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [3-Hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 157953-13-4
• 化学式: C₂₉H₅₆NO₉P
• 分子量: 593.739
• InChiKey: RKIDALSACBQVTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  40
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  128
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3-(4-氨基苯基)丙酸 、 [3-Hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  Nanoparticle-Based Detection of Oxidized Phospholipids by MALDI Mass Spectrometry: Nano-MALDI Approach

  摘要：

  在本文中，我们介绍了一种利用纳米粒子（NPs）通过 MALDI-MS（即 Nano-MALDI 方法）对 OxPLs 进行 "探针式"（即直接从 NP 表面）监测的开创性方法。利用与金属氧化物（如 ZrO2）或表面功能化的 Fe3O4 核壳超顺磁性 NPs（直径为 100 nm）的 "亲电相互作用"，可直接富集短链羧基（CARBO）-OxPLs，而检测醛基（ALDO）-OxPLs 则需要事先用含有负电荷分子（如 4-AA）的双功能羰基反应试剂进行衍生，然后再与 NP 结合。聚醚胺（PEA）-NPs 在溶剂稳定性、结合效率以及与 MALDI-MS 分析的兼容性方面都是最合适的。为了对 OxPLs 进行定量分析，采用了最近推出的 MALDI-QIT-TOF-MS/MS 平台（Stübiger 等，Atherosclerosis 2012, 224, 177-186），并通过 LC-ESI-SRM-MS/MS 进行交叉验证。发现灵敏度在亚纳摩尔范围内（LOD ∼200 pM），比在正常和疾病条件下（如小鼠血浆或人类脂蛋白中）检测单个 OxPLs 所需的灵敏度高 1-4 个数量级。因此，Nano-MALDI 方法有望成为生物样本中 OxPLs 的新型筛选平台，并在未来开发临床诊断测试。

  DOI：

  10.1021/ac500719u

文献信息

• STABILIZED DENATURED LIPOPROTEIN AND PROCESS FOR PRODUCING THE SAME
  申请人：Vessel Research Laboratory Co., Ltd.

  公开号：EP1184392A1

  公开（公告）日：2002-03-06

  Denatured lipoprotein excelling in stability of prolonged preservation (namely exhibiting only sparing liability to induce denaturation of lipoprotein) and used as a standard substance for the determination of denatured lipoprotein in blood or the determination of the physiological activity of the lipoprotein and a method for the production thereof are provided. The method for the production of the stabilized denatured lipoprotein comprises artificially denaturing lipoprotein, thereby obtaining denatured lipoprotein, freeze-drying the denatured lipoprotein or performing a process including at least one freezing operation on a solution containing denatured lipoprotein thereby denaturing the lipoprotein contained in the solution and obtaining denatured lipoprotein and further freeze-drying the denatured lipoprotein.

  本发明提供了在长期保存稳定性方面表现优异的变性脂蛋白（即只表现出很少的诱发脂蛋白变性的责任），并用作测定血液中变性脂蛋白或测定脂蛋白生理活性的标准物质及其生产方法。生产稳定变性脂蛋白的方法包括人工使脂蛋白变性，从而获得变性脂蛋白，冷冻干燥变性脂蛋白，或对含有变性脂蛋白的溶液进行包括至少一次冷冻操作的处理，从而使溶液中所含的脂蛋白变性，获得变性脂蛋白，并进一步冷冻干燥变性脂蛋白。
• STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：EP4061409A1

  公开（公告）日：2022-09-28
• SURFACE-TREATED MAGNESIUM OR CALCIUM ION-CONTAINING MATERIALS AS WHITE PIGMENTS IN ORAL CARE COMPOSITIONS
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20220370310A1

  公开（公告）日：2022-11-24

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.
• Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
  申请人：Children's Medical Center Corporation

  公开号：US20220401535A1

  公开（公告）日：2022-12-22

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy.
• [EN] STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY<br/>[FR] STIMULI HYPERACTIVANT DES CELLULES DENDRITIQUES RÉSIDENTES POUR L'IMMUNOTHÉRAPIE ANTICANCÉREUSE
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2021102058A1

  公开（公告）日：2021-05-27

  The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.